Table 1.
Baseline patient characteristics.
| Character | No./Median | Percentage/Range |
|---|---|---|
|
| ||
| Age | 57 | (24–86) |
|
| ||
| Sex | ||
| Male | 28 | (57%) |
| Female | 21 | (43%) |
|
| ||
| Prior liver resection | ||
| Yes | 22 | (45%) |
| No | 27 | (55%) |
|
| ||
| Prior HAIC | ||
| Yes | 26 | (53%) |
| No | 23 | (47%) |
|
| ||
| Prior lines of systemic chemotherapy | ||
| 2 | 35 | (71%) |
| ≥3 | 14 | (29%) |
|
| ||
| Prior chemotherapeutic agents received | ||
| Capecitabine | 17 | (35%) |
| 5 FU/LV | 45 | (91%) |
| Oxaliplatin | 47 | (96%) |
| Irinotecan | 45 | (92%) |
|
| ||
| Prior biological agents received | ||
| Bevacizumab | 38 | (78%) |
| Cetuximab | 22 | (45%) |
| Panitumumab | 5 | 10%) |
|
| ||
| Prior treatments for liver metastasis | ||
| Resection + HAIC + systemic chemotherapy | 17 | (35%) |
| Resection + systemic chemotherapy | 5 | (10%) |
| HAIC + systemic chemotherapy | 9 | (18%) |
| Systemic chemotherapy | 18 | (37%) |
|
| ||
| Extrahepatic disease | ||
| No | 9 | (18%) |
| Lung only | 13 | (27%) |
| Lymph nodes only | 5 | (10%) |
| Lung + lymph nodes | 11 | (23%) |
| Other 2 sites | 4 | (8%) |
| Multiple sites | 7 | (14%) |
|
| ||
| Extent of liver replacement by tumor | ||
| <25% | 44 | (90%) |
| ≥25% | 5 | (10%) |
|
| ||
| Baseline CEA (ng/ml) | 82 | (2.7-23938) |
|
| ||
| Number of target lesions/patient | ||
| 1 | 17 | (33%) |
| 2 | 10 | (22%) |
| 3 | 9 | (18%) |
| 4 | 10 | (21%) |
| 5 | 3 | (6%) |
|
| ||
| Treatment | ||
| 1 session | 36 | (73%) |
| 2 sessions | 13 | (27%) |
HAIC: Hepatic Arterial Infusion Chemotherapy